These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21876448)

  • 1. Longitudinal assessment of interleukin 7 plasma levels in HIV-infected patients in the absence of and under antiretroviral therapy.
    Rallón NI; López M; Lozano S; Sempere-Ortells JM; Soriano V; Benito JM
    J Acquir Immune Defic Syndr; 2011 Dec; 58(5):436-41. PubMed ID: 21876448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
    Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
    J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
    Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
    J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression.
    Camargo JF; Kulkarni H; Agan BK; Gaitan AA; Beachy LA; Srinivas S; He W; Anderson S; Marconi VC; Dolan MJ; Ahuja SK
    J Infect Dis; 2009 Jun; 199(12):1872-82. PubMed ID: 19432535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy.
    Darcissac EC; Vidal V; De La Tribonniere X; Mouton Y; Bahr GM
    Clin Exp Immunol; 2001 Nov; 126(2):287-94. PubMed ID: 11703373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies.
    Martín JC; Soriano V; Jiménez-Nácher I; Martínez P; González-Lahoz J
    Clin Microbiol Infect; 2001 Dec; 7(12):678-81. PubMed ID: 11843909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.
    Henry K; Katzenstein D; Cherng DW; Valdez H; Powderly W; Vargas MB; Jahed NC; Jacobson JM; Myers LS; Schmitz JL; Winters M; Tebas P;
    J Acquir Immune Defic Syndr; 2006 Jun; 42(2):140-8. PubMed ID: 16760795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.
    Gerna G; Piccinini G; Genini E; Percivalle E; Zavattoni M; Lilleri D; Testa L; Comolli G; Maserati R; Baldanti F; Maccario R; Monforte AD; Revello MG
    J Acquir Immune Defic Syndr; 2001 Dec; 28(4):320-31. PubMed ID: 11707667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher levels of HIV DNA in memory and naive CD4(+) T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART.
    Baldanti F; Paolucci S; Gulminetti R; Maserati R; Migliorino G; Pan A; Maggiolo F; Comolli G; Chiesa A; Gerna G
    Antiviral Res; 2001 Jun; 50(3):197-206. PubMed ID: 11397507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.
    Benito JM; López M; Lozano S; Ballesteros C; Martinez P; González-Lahoz J; Soriano V
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):373-81. PubMed ID: 15764953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating levels of interleukin-7 in antiretroviral-naïve and highly active antiretroviral therapy-treated HIV-infected patients.
    Mastroianni CM; Forcina G; d'Ettorre G; Lichtner M; Mengoni F; D'Agostino C; Vullo V
    HIV Clin Trials; 2001; 2(2):108-12. PubMed ID: 11590518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV DNA and immune alteration during successful HAART.
    Mamadou D; Yu-Huang Z; Xia C; Bo H; Hua-Ying Z; Yan H; Zi C; Qing L; Li-Wen Z; Mei H; Yun-Hai Y; Demba S; Aldebert D; Souleymane M
    Curr HIV Res; 2013 Jun; 11(4):255-62. PubMed ID: 23822818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homeostatic role of IL-7 in HIV-1 infected children on HAART: association with immunological and virological parameters.
    Resino S; Galán I; Correa R; Pajuelo L; Bellón JM; Muñoz-Fernández MA
    Acta Paediatr; 2005 Feb; 94(2):170-7. PubMed ID: 15981750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients.
    Clerici M; Seminari E; Maggiolo F; Pan A; Migliorino M; Trabattoni D; Castelli F; Suter F; Fusi ML; Minoli L; Carosi G; Maserati R;
    AIDS; 2002 Sep; 16(13):1767-73. PubMed ID: 12218388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
    Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
    AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.